Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • ALDOB K87 Lactylation Links Mitochondrial Fission to PH Prog

    2026-04-27

    ALDOB K87 Lactylation Drives Mitochondrial Fission in Pulmonary Hypertension

    Study Background and Research Question

    Pulmonary hypertension (PH) is a severe vascular disorder marked by progressive remodeling of the pulmonary arteries, leading to elevated pulmonary pressure and eventual right heart failure. Despite advances in vasodilator therapies, the fundamental molecular drivers of vascular remodeling and smooth muscle cell proliferation remain incompletely understood (Yi et al., 2026). Recent attention has turned to the role of metabolic reprogramming—specifically, the shift from oxidative phosphorylation to aerobic glycolysis (the Warburg effect)—and its impact on the proliferation and phenotype of pulmonary artery smooth muscle cells (PASMCs). However, the coupling mechanisms linking altered metabolism, mitochondrial dynamics, and epigenetic regulation in PH pathogenesis have not been fully elucidated.

    Key Innovation from the Reference Study

    Yi et al. (2026) introduce a novel mechanistic link between lactate metabolism and mitochondrial dynamics in PH by focusing on the post-translational modification of aldolase B (ALDOB), a glycolytic enzyme. Using integrated lactylomic profiling, the authors identify lactylation of ALDOB at lysine-87 (K87) as a critical event induced by hypoxic stress in PASMCs. This modification recruits dynamin-related protein 1 (DRP1) to mitochondria after SUMO-specific peptidase 3–mediated deSUMOylation, promoting mitochondrial fission. The study positions ALDOB K87 lactylation as a pivotal regulator of both metabolic rewiring and mitochondrial fragmentation, directly contributing to the pathological proliferation and migration of PASMCs (Yi et al., 2026).

    Methods and Experimental Design Insights

    The research employed a multifaceted experimental approach:
    • Lactylome sequencing was performed on hypoxic human PASMCs to map changes in protein lactylation.
    • Rodent models of PH were used to validate in vitro findings and assess in vivo relevance.
    • Genetic manipulation (knockdown and overexpression) of ALDOB and DRP1, along with pharmacological modulation of lactylation, were applied to dissect pathway specificity.
    • Phenotypic assays measured PASMC proliferation, migration, and mitochondrial morphology under different conditions.
    • Sirtuin 1 activity was analyzed as a potential delactylase regulating ALDOB lactylation status.
    This integrated methodology allowed the authors to not only identify the modification but also causally link it to mitochondrial fission and PASMC behavior.

    Protocol Parameters

    • assay | hypoxic culture duration | 24-72 h | models metabolic stress in PASMCs | mimics in vivo PH conditions | paper
    • assay | ALDOB knockdown efficiency | ≥80% suppression | required for phenotype rescue | ensures pathway specificity | paper
    • assay | pharmacological lactylation inhibitor dose | 1-10 μM | titrated in vitro | confirms modification-dependence of phenotype | paper
    • assay | cell proliferation assay with PDGF-BB | 2-10 ng/ml | positive control for mitogen responsiveness | validates PASMC proliferative capacity | workflow_recommendation

    Core Findings and Why They Matter

    The study provides several critical insights:
    • Hypoxia-Induced ALDOB K87 Lactylation: Hypoxic conditions enhance global protein lactylation, with ALDOB K87 emerging as a dominant non-histone target. This is accompanied by a self-reinforcing loop, as increased glycolytic flux generates more lactate, further driving ALDOB lactylation (Yi et al., 2026).
    • Mitochondrial Fission and PASMC Proliferation: ALDOB K87 lactylation is necessary for DRP1 recruitment to mitochondria, promoting mitochondrial fragmentation—a hallmark of highly proliferative, metabolic-rewired PASMCs. Genetic or pharmacological suppression of ALDOB lactylation attenuates these effects and reduces disease progression in rodent PH models.
    • Sirtuin 1 as a Negative Regulator: SIRT1, a known delactylase, is downregulated in PH, perpetuating ALDOB K87 lactylation and its downstream consequences. This identifies an additional regulatory axis that may be therapeutically exploitable.
    These findings not only define a lactate–ALDOB–DRP1 axis in PH but also demonstrate the integral relationship between metabolic flux, post-translational modification, and mitochondrial dynamics.

    Comparison with Existing Internal Articles

    Several internal resources provide complementary context: The reference study advances the mechanistic underpinnings described in these internal articles by providing a direct molecular pathway linking metabolic stress to mitochondrial and proliferative changes in vascular cells.

    Limitations and Transferability

    While the study delivers compelling mechanistic evidence, several limitations should be noted:
    • Pre-publication Status: The results are from an in-press manuscript and may be subject to further revision.
    • Species and Model Specificity: The primary findings derive from human cell lines and rodent models; their direct applicability to human PH patients will require further clinical validation.
    • Complexity of In Vivo Regulation: While the ALDOB–DRP1 axis is clearly implicated, additional regulatory mechanisms may contribute to PH pathogenesis in vivo, and the potential off-target effects of manipulating lactylation remain to be fully characterized.
    Nevertheless, the core lactylation mechanism and its impact on mitochondrial fission represent a robust framework for future PH research and therapeutic exploration.

    Research Support Resources

    For researchers aiming to investigate smooth muscle cell proliferation, metabolic rewiring, or mitochondrial function in vascular contexts, defined mitogenic stimuli remain essential. The PDGF-BB, murine recombinant protein (SKU P1048) from APExBIO provides a validated, non-glycosylated recombinant growth factor suitable for cell proliferation assays. Its confirmed mitogen activity on murine BALB/c 3T3 cells (ED50 <2 ng/ml) makes it a reliable positive control for smooth muscle and connective tissue cell proliferation workflows (source: product_spec; workflow_recommendation). When designing experimental protocols aligned with the mechanisms described by Yi et al. (2026), careful titration and assay optimization with defined recombinant PDGF-BB can enhance reproducibility and interpretive power in in vitro models of vascular remodeling.